Search Result

Results for "

Ranolazine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (2) Biochemical Assay Reagents (1) Calcium Channel (7) Isotope-Labeled Compounds (2) Sodium Channel (8)
By Research Areas:	Cancer (7) Cardiovascular Disease (9)

Inhibitors & Agonists

Biochemical Assay Reagents

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0280

*Ranolazine* 4 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-dd₈ dihydrochloride; RS 43285-d₈	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-17401

Ranolazine dihydrochloride 4 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-W009512

CVT-2738 RS-94287	Others	Cardiovascular Disease
CVT-2738 is a Ranolazine (HY-B0280) Metabolite, and shows anti-myocardial ischemia activities .

HY-B0280R

Ranolazine (Standard)	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-W700345

*Desmethyl ranolazine* β-D-glucuronide**	Biochemical Assay Reagents	Others
Desmethyl ranolazine β-D-glucuronide is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-Glycan recognition and the role of glycans in biological systems. This field is closely related to basic research, biomedicine and biotechnology.

HY-163637

Sodium Channel inhibitor 5	Sodium Channel	Cardiovascular Disease
Sodium Channel inhibitor 5 (compound 7d) is a potent inhibitor of sodium channel, with the IC₅₀ of 2.7 μM. Sodium Channel inhibitor 5 plays an important role in antiarrhythmic research .

Cat. No.	Product Name	Type

HY-W700345

*Desmethyl ranolazine* β-D-glucuronide**	Carbohydrates
Desmethyl ranolazine β-D-glucuronide is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-Glycan recognition and the role of glycans in biological systems. This field is closely related to basic research, biomedicine and biotechnology.

Desmethyl ranolazine β-D-glucuronide

Carbohydrates

Desmethyl ranolazine β-D-glucuronide is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-Glycan recognition and the role of glycans in biological systems. This field is closely related to basic research, biomedicine and biotechnology.

Cat. No.	Product Name	Chemical Structure

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-17401S

Ranolazine-d8 dihydrochloride
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.